The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer
Authors
Keywords
Apoptosis, Cancer treatment, Ovarian cancer, Cell cycle and cell division, Surgical and invasive medical procedures, Cell staining, Histones, Surgical oncology
Journal
PLoS One
Volume 11, Issue 6, Pages e0158208
Publisher
Public Library of Science (PLoS)
Online
2016-06-29
DOI
10.1371/journal.pone.0158208
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Panobinostat: First Global Approval
- (2015) Karly P. Garnock-Jones DRUGS
- First In-Mouse Development and Application of a Surgically Relevant Xenograft Model of Ovarian Carcinoma
- (2014) Øystein Helland et al. PLoS One
- Molecular Epigenetics in the Management of Ovarian Cancer: Are We Investigating a Rational Clinical Promise?
- (2014) Ha T. Nguyen et al. Frontiers in Oncology
- Effects of Valproic Acid on Proliferation, Apoptosis, Angiogenesis and Metastasis of Ovarian Cancer in Vitro and in Vivo
- (2013) Zhao Shan et al. Asian Pacific Journal of Cancer Prevention
- Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin
- (2013) Andrés Poveda et al. CANCER TREATMENT REVIEWS
- Panobinostat in lymphoid and myeloid malignancies
- (2013) Amit Khot et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Optimizing treatment of the partially platinum-sensitive ovarian cancer patient
- (2013) Nicoletta Colombo Future Oncology
- A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
- (2013) Sunil Sharma et al. INVESTIGATIONAL NEW DRUGS
- Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer
- (2013) Peter M. Wilson et al. INVESTIGATIONAL NEW DRUGS
- Profile of panobinostat and its potential for treatment in solid tumors: an update
- (2013) Madhurima Anne et al. OncoTargets and Therapy
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Prevention and handling of acute allergic and infusion reactions in oncology
- (2012) M. Joerger ANNALS OF ONCOLOGY
- Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro
- (2012) Hongtu Chao et al. CANCER LETTERS
- Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer
- (2012) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metronomic therapy for gynecologic cancers
- (2012) Wen-Hsiang Su et al. Taiwanese Journal of Obstetrics & Gynecology
- Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives
- (2011) J. Sehouli et al. ANNALS OF ONCOLOGY
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
- (2011) Gavin C.E. Stuart et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- The challenge of selecting the ‘right’ in vivo oncology pharmacology model
- (2010) Brant Firestone CURRENT OPINION IN PHARMACOLOGY
- A work in progress: The clinical development of histone deacetylase inhibitor
- (2010) Silvia Marsoni et al. Epigenetics
- The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines
- (2010) Daniel R. Budman et al. INVESTIGATIONAL NEW DRUGS
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
- (2010) Michael Dickinson et al. INVESTIGATIONAL NEW DRUGS
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
- (2009) H Miles Prince et al. Future Oncology
- Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer
- (2009) Noriyuki Takai et al. Journal of Oncology
- Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues
- (2008) Ke Long Jin et al. Journal of Gynecologic Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started